Portfolio
Overview

Watchlist
Overview


more

Portfolios Overview New Portfolio
Demo Portfolio
$70,775.00
Total Gain % 122.46%
Total Gain $20,775.00
Total Realised % 0.00%
Total Realised $0.00
Back
Watchlists Overview New Watchlist
Targets
48 Average Rating
Number of Companies 3
Date Created 04 Mar, 2015
Back
Portfolio Summary
Demo Portfolio
Market Value $70,775.00
Total Gain $20,775.00
(122.46%)
Value $37,740.00
Close Price (05 May) $125.80
Unrealised P/L (%) 122.46%
Unrealised P/L $20,775.00
Total $70,775.00
$20,775.00
Back
Back
Watchlist Summary
Targets
Short Name TGTS
Date Created 04 Mar, 2015
Current Price $47.60
Added Price $43.28
STRIDE Rating 49
Value Change (%) 9.98%
Current Price $34.12
Added Price $34.56
STRIDE Rating 32
Value Change (%) -1.27%
Current Price $28.04
Added Price $29.66
STRIDE Rating 67
Value Change (%) -5.46%
Total Buy0
Total Hold2
Total Sell1
Back
Back
Filter
Include in Feed
My Portfolios
My Watchlists
STRIDE Lists
Filter Feed By
STRIDE 3D VI
Activity
Upcoming
Warning
Back
Company FilterClear All
Filter by Company Descriptions
Filter by STRIDE Scores
Strength
to
Timing
to
Returns
to
Intrinsic Value
to
Dividends
to
Earnings Predictability
to
Rating
to
Back
Options
Add To Watchlist
Company Info (Sample)
Options
Add To Watchlist

A1M Pharma AB

A1M Pharma AB
Pharmaceuticals, Biotechnology and Life Sciences : Biotechnology.
A1M on OMX Nordic Exchange Stockholm.
Price in Swedish Krona, all financial data originally reported in Swedish Krona.
The business last filed accounts on the 10 Apr, 2015.
Company website: www.a1m.se
Show Company Details
STRIDE Rating
00
Buy
Hold
Sell
Sweden, Micro Cap
Market Capitalisation: k265.18M
Total Enterprise Value: Free Trial
A1M Pharma AB is engaged in the research, development, and commercialization of drugs for intravenous treatment of pre-eclampsia in Sweden. The company specializes in the development of treatment for pre-eclampsia based on alpha-1-microglobulin protein; and the early diagnosis of the disease using fetal hemoglobin. A1M Pharma AB is based in Lund, Sweden. Read More
Company Feed
03 May STRIDE has calculated that this business has no True Book Value. The STRIDE view of the balance sheet graph will not balance as we believe there is a 'hole' in the balance sheet. Proceed with caution.
03 May This business has a recent filing made on the 10th April 2015.
Price & Valuation Info
Price Quote on 5th May '15
k9.15 0.35(3.98%)
52 Week Range
2.62
10.9
Interactive STRIDE chart with history.
Only available to subscribers.
Free Trial now.
Performance
1 month -0.10 (-1.08%)
year-to-date 5.30 (137.66%)
1 year 4.50 (96.77%)
Show More Valuation Info
Momentum
vs 52week high 84%
vs 50d SMA 107%
vs 200d SMA146%
STRIDE Valuations
Consider Buy Free Trial
Fair Value Free Trial
Consider Sell Free Trial
Price/Adj. Earnings Free Trial
Price/Adj FCF Free Trial
Price/Adj. TBV Free Trial
Forecast Growth Free Trial
Other Valuations
Price/Book Free Trial
Price/Tangible Book Free Trial
Price/Sales Free Trial
Price/Earnings Free Trial
Price/Free Cashflow Free Trial
EV/EBITDA Free Trial
Dividend Yield Free Trial
Volume
Ave. Vol. last 6 months
Hide Extra Info
Scores
S
Strength
T
Timing
R
Returns
I
Intrinsic Value
D
Dividends
E
Earnings Predictability
Other Metrics
Altman Z-Score (Bankruptcy)
Greenblatt Rank (Magic Formula)
Piotroski F-Score (Financial Health)
Beneish M-Score (Earnings Manipulation)
Financials Free Trial
To The Top
Company Options
Add To Watchlist
Watchlists:
Targets
Options
Price Alert Email:
Price to alert at:*
When to alert:*
Cancel
Save
Price Alerts Configured:
Back

Portfolio
Overview

Watchlist
Overview

Feed
Filter


more